View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 6, 2016updated 13 Jul 2022 10:15am

Teva and HSG report Phase III trial results of SD-809 to treat Huntington disease

Israel-based pharmaceutical company Teva Pharmaceutical and Huntington Study Group (HSG) have reported results of the Phase III trial of SD-809 (deutetrabenazine) tablets to treat chorea associated with Huntington disease (HD).

HD

Israel-based pharmaceutical company Teva Pharmaceutical and Huntington Study Group (HSG) have reported results of the Phase III trial of SD-809 (deutetrabenazine) tablets to treat chorea associated with Huntington disease (HD).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

SD-809 (deutetrabenazine) is an investigational, orally administered small-molecule that inhibits vesicular monoamine 2 transporter (VMAT2).

The Phase III trial is a placebo-controlled and randomised First-HD (First Time Use of SD-809 in Huntington Disease) study designed to determine the safety and efficacy of SD-809.

It involved 90 patients afflicted with HD who were randomised 1:1 to be administered with SD-809 or placebo.

Huntington Study Group executive committee member and First-HD trial principal investigator Dr Samuel Frank said: "As a physician who cares for people with HD, it’s gratifying to see positive results from a well-designed, fully enrolled trial.

"Until we find a cure, we aim to bring our patients more treatment options to relieve symptoms.

"Until we find a cure, we aim to bring our patients more treatment options to relieve symptoms."

"We are grateful to the people who participated in this trial, along with their families and support systems that made their participation possible. Research in the HD community depends on volunteers enrolling in trials."

HD is a fatal neurodegenerative disease, symptoms of which are uncoordinated and uncontrollable movements such as chorea, cognitive deterioration and behavioural and / or psychological problems.

The symptoms generally tend to occur during middle age, but the disease can also be present in children and the elderly.

The company is also exploring the efficacy of deutetrabenazine in treating tardive dyskinesia and for tics associated with Tourette syndrome.


Image: Microscopic image of neuron with inclusion caused by HD. Photo: courtesy of Leevanjackson via Wikipedia.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena